PMID- 35565405
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 9
DP  - 2022 May 3
TI  - Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer 
      Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center 
      Cohort Study.
LID - 10.3390/cancers14092276 [doi]
LID - 2276
AB  - Immune checkpoint inhibitors (ICIs) are associated with immune-related (ir) 
      adverse events (AEs) resembling autoimmune diseases. In this retrospective cohort 
      study of patients (pts) treated with ICIs at Oulu University Hospital from 
      2014-2020, we analysed the spectrum of severe irAEs and their prognostic nature, 
      focusing on rare irAEs. Pts (n = 173) with lung cancer (n = 76, 43.9%), melanoma 
      (n = 56, 32.4%), renal and bladder cancers (n = 34, 19.7%), head and neck cancers 
      (n = 4, 2.3%), SCC (n = 2, 1.2%), and CRC (n = 1, 0.6%) receiving single 
      anti-PD-(L)1 (n = 160) or combination (ICI-ICI n = 9, ICI-chemotherapy n = 4) 
      therapy were included. The survival analysis focused on single 
      anti-PD-(L)1-treated patients with melanoma, lung cancer, and renal and bladder 
      cancers (n = 142). Grade >/= 3 irAEs of multiple aetiology occurred in 29 patients 
      treated with single-PD-L1 therapy (20.4%), which was associated with improved 
      progression-free survival (PFS) (HR 0.50, CI 0.31-0.78) but not overall survival 
      (OS) (HR 0.88, CI 0.52-1.50). Rare grade >/= 3 events occurred in 10 (7.0%) pts 
      with no association with PFS (HR 0.90, CI 0.42-1.94). Hence, the presence of rare 
      grade >/= 3 irAEs was associated with a tendency for inferior OS (HR 1.44, CI 
      0.66-3.11). Pts with rare grade >/= 3 irAEs had inferior OS, possibly reflecting 
      the delay in diagnostic workflow and the treatment of irAEs. One explanation for 
      the high incidence of irAEs could be the Finnish population-based genetic 
      variation affecting the immune system.
FAU - Kuusisalo, Saara
AU  - Kuusisalo S
AD  - Department of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, 
      90220 Oulu, Finland.
FAU - Koivunen, Jussi P
AU  - Koivunen JP
AD  - Department of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, 
      90220 Oulu, Finland.
FAU - Iivanainen, Sanna
AU  - Iivanainen S
AUID- ORCID: 0000-0003-1075-1134
AD  - Department of Oncology and Radiotherapy, Oulu University Hospital and MRC Oulu, 
      90220 Oulu, Finland.
LA  - eng
GR  - NA/Oulu University/
GR  - NA/The Emil Aaltonen Foundation/
GR  - NA/The Finnish Medical Foundation/
GR  - NA/Finnish Cancer Society/
PT  - Journal Article
DEP - 20220503
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9103509
OTO - NOTNLM
OT  - autoimmunity
OT  - immune checkpoint inhibitors
OT  - immune-related adverse event
OT  - prognostic
OT  - survival
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/15 06:00
MHDA- 2022/05/15 06:01
PMCR- 2022/05/03
CRDT- 2022/05/14 01:18
PHST- 2022/03/22 00:00 [received]
PHST- 2022/04/29 00:00 [revised]
PHST- 2022/05/01 00:00 [accepted]
PHST- 2022/05/14 01:18 [entrez]
PHST- 2022/05/15 06:00 [pubmed]
PHST- 2022/05/15 06:01 [medline]
PHST- 2022/05/03 00:00 [pmc-release]
AID - cancers14092276 [pii]
AID - cancers-14-02276 [pii]
AID - 10.3390/cancers14092276 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 May 3;14(9):2276. doi: 10.3390/cancers14092276.